- Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company ...
Q3 2025 Earnings Call Transcript November 12, 2025 Humacyte, Inc. beats earnings expectations. Reported EPS is $-0.14, ...
DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte, Inc. ( HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback